Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PRSD | 24.72 | 0.07 | +0.30% |
| State Street Short Duration IG Public & Private Credit ETF (PRSD) | |||
| AELV | 26.22 | N/A | N/A |
| Harbor AlphaEdge Large Cap Value ETF (AELV) | |||
| AOM | 47.57 | -0.33 | -0.69% |
| iShares Core 40/60 Moderate Allocation ETF (AOM) | |||
| LCOW | 25.81 | -0.50 | -1.90% |
| Pacer S&P 500 Quality FCF Aristocrats ETF (LCOW) | |||
| CLOU | 24.78 | -0.70 | -2.75% |
| Global X Cloud Computing ETF (CLOU) | |||
A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with ABEO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then ABEO could also see price increases.
| Ticker / NAME | Correlation To ACAD | 1D Price Change % | ||
|---|---|---|---|---|
| ACAD | 100% | -1.35% | ||
| ABEO - ACAD | 58% Loosely correlated | -10.26% | ||
| ZURA - ACAD | 58% Loosely correlated | -1.32% | ||
| CLDX - ACAD | 45% Loosely correlated | +1.49% | ||
| MGTX - ACAD | 45% Loosely correlated | -2.16% | ||
| STOK - ACAD | 44% Loosely correlated | +0.90% | ||
More | ||||
a developer of pharmaceuticals drugs for treatment of central nervous system disorders
Industry Biotechnology
ACAD saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 33 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 72%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACAD as a result. In 64 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The 50-day moving average for ACAD moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for ACAD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACAD's RSI Oscillator exited the oversold zone, 15 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 55 cases where ACAD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +11.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACAD advanced for three days, in 189 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
ACAD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. ACAD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.800) is normal, around the industry mean (3.596). P/E Ratio (9.394) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.168) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.